SAGO 2025 Official Aftermovie
Your browser does not support the video tag.
Fitness Breaks at SAGO 2025
Your browser does not support the video tag.
Dear friends,
Thank you for participating in SAGO 2025 in Prague.
I am thrilled with the feedback from participants and speakers alike. I believe that the concept of an intensive two-day conference proved successful, that the entire two days were interesting, and that the atmosphere was very open and friendly. Not to mention the world premiere of fitness breaks during the program.
All recorded lectures from the conference will also be available, after some processing, to participants on the same platform for six months after the meeting.
We will do our best to meet again in Prague at SAGO 2027.
Wishing you all the best.
David Cibula
Your browser does not support the video tag.
Program
click here
Diagnostics and staging
Rational use of imaging methods in gynecological oncology
Preoperative staging of pelvic masses
Assessment of lymph nodes by US, PET and MRI
Pelvic side wall anatomy and assessment
Imaging guided procedures
Perioperative and palliative care
Implementation of ERAS and prehabilitation into the routine practice
Early palliative care and best supportive care in gynecological oncology
Communicating serious news effectively: Tips and tricks for a person-centered approach
Live ultrasound scanning
LIVE demonstration of ultrasound examination of patients with gynecological tumors.
Videosession
Demonstration of main radical surgical procedures step by step.
Systemic treatment
Systemic treatment of ovarian cancer
What is BRCA, HRD, HRR, and how they are tested
Biomarkers in ovarian cancer – which and when
Current SoA chemotherapy
Maintenance treatment in 1L and beyond
Platinum resistant recurrent ovarian cancer (PROC)
Current SoA treatment of PROC
What is ADC and how it works
Predictive biomarkers and their testing
First ADC approved in ovarian cancer in Europe
Challenging management of new types of toxicity
Systemic treatment
Management of locally advanced and metastatic cervical cancer
Chaos in classification (intermediate/ high risk, IB3, locally advanced disease)
What is the current standard treatment in locally advanced cervical cancer (chemoradiotherapy vs induction chemo vs immunotherapy)
First line treatment of metastatic disease
Tips how to manage toxicity and enhance treatment compliance
Endometrial cancer
Molecular classification in endometrial cancer for beginners
Indications of adjuvant treatment in the molecular era
Systemic treatment of metastatic and recurrent endometrial cancer
Immunotherapy and endocrine treatment
A guide to cancer immunotherapy
Principles of cancer immunotherapy strategies
Endocrine treatment in gynaecological tumors
The role of NGS and molecular tumor boards in current management
Surgical treatment
Early stages
Surgical treatment of non-epithelial and other rare ovarian tumors
Surgical treatment of early-stage cervical cancer in the “after SHAPE” era
Sentinel lymph nodes in gynecological cancers
Management of patients with micrometastases and isolated tumor cells in SLN
Fertility sparing treatment
Fertility preservation in cervical cancer
Fertility preservation in endometrial cancer
Management of gynecological tumors in pregnancy
Advanced stages
Secondary cytoreduction in ovarian and endometrial cancer
Pelvic exenterations, LEER and out-of-box procedures
Compliance
We are pleased to inform you that the State-of-the-Art Congress in Gynecologic Oncology
has been determined as compliant with MedTech Europe Code of Ethical Business Practice and EFPIA Code of Practice .
This decision is posted here .